Flexion Therapeutics Inc FLXN
We take great care to ensure that the data presented and summarized in this overview for Flexion Therapeutics Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in FLXN
Top Purchases
Top Sells
About FLXN
Insider Transactions at FLXN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2021
|
Newtyn Management, LLC > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,900,000
-100.0%
|
-
|
|
Nov 19
2021
|
Michael D. Clayman President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
787,052
-100.0%
|
$6,296,416
$8.5 P/Share
|
|
Nov 19
2021
|
Michael D. Clayman President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
335,498
-100.0%
|
$2,683,984
$8.5 P/Share
|
|
Nov 19
2021
|
William T. Andrews Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
34,250
-100.0%
|
$274,000
$8.5 P/Share
|
|
Nov 19
2021
|
Frederick W Driscoll Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,680
-100.0%
|
$245,440
$8.5 P/Share
|
|
Nov 19
2021
|
Christina Willwerth Chief Strategy Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
141,241
-100.0%
|
$1,129,928
$8.5 P/Share
|
|
Nov 19
2021
|
Melissa Layman Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
103,956
-100.0%
|
$831,648
$8.5 P/Share
|
|
Nov 19
2021
|
Kerry Wentworth Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
6,000
-100.0%
|
$48,000
$8.5 P/Share
|
|
Nov 19
2021
|
Kerry Wentworth Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
140,843
-100.0%
|
$1,126,744
$8.5 P/Share
|
|
Nov 19
2021
|
Adam Muzikant Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
103,666
-100.0%
|
$829,328
$8.5 P/Share
|
|
Nov 19
2021
|
Mark S. Levine General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
133,486
-100.0%
|
$1,067,888
$8.5 P/Share
|
|
Nov 19
2021
|
Patrick J Mahaffy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,824
-100.0%
|
$318,592
$8.5 P/Share
|
|
Nov 19
2021
|
Scott A Canute Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
$72,000
$8.5 P/Share
|
|
Nov 19
2021
|
Samuel D Colella Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,487,564
-100.0%
|
$11,900,512
$8.5 P/Share
|
|
Nov 19
2021
|
Samuel D Colella Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
$72,000
$8.5 P/Share
|
|
Nov 19
2021
|
Elizabeth Kwo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,500
-100.0%
|
$36,000
$8.5 P/Share
|
|
Nov 19
2021
|
Heath Lukatch Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
$72,000
$8.5 P/Share
|
|
Nov 19
2021
|
C Ann Merrifield Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,000
-100.0%
|
$152,000
$8.5 P/Share
|
|
Nov 19
2021
|
Alan Milinazzo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,450
-100.0%
|
$219,600
$8.5 P/Share
|
|
Nov 19
2021
|
Mark Stejbach Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,631
-100.0%
|
$101,048
$8.5 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders